Eli Lilly (LLY) Net Income - Minority (2009 - 2015)
Eli Lilly (LLY) posted Net Income - Minority of -$19.0 million for Q4 2015, down 27.52% quarter-over-quarter from -$14.9 million in Q4 2014, and down 27.52% year-on-year from -$26.2 million in Q4 2014.
Eli Lilly (LLY) Net Income - Minority (2009 - 2015) Analysis & Trends
Eli Lilly (LLY) has reported Net Income - Minority for 6 consecutive years, with -$19.0 million the latest figure, recorded in Q4 2015.
- Net Income - Minority for Q4 2015 came in at -$19.0 million, down 27.52% year-over-year; the trailing twelve-month figure through Dec 2015 was -$19.0 million (down 27.52% YoY), and the FY2015 annual result was -$19.0 million, down 27.52% from the prior year.
- Net Income - Minority was -$19.0 million for Q4 2015 at Eli Lilly, down from -$14.9 million in the prior quarter.
- Over five years, Net Income - Minority peaked at $6.1 million in Q4 2011 and troughed at -$19.0 million in Q4 2015.
- Average Net Income - Minority over 5 years is -$9.2 million, with a median of -$9.3 million recorded in 2013.
- Year-over-year, Net Income - Minority slumped 242.62% in 2012 and retreated 6.9% in 2013.
- Over 5 years, Net Income - Minority stood at $6.1 million in 2011, then plunged by 242.62% to -$8.7 million in 2012, then decreased by 6.9% to -$9.3 million in 2013, then tumbled by 60.22% to -$14.9 million in 2014, then fell by 27.52% to -$19.0 million in 2015.
- Per Business Quant data, the three most recent Net Income - Minority figures were -$19.0 million in Q4 2015, -$14.9 million in Q4 2014, and -$9.3 million in Q4 2013.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income - Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | - |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | - |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | - |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | - |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | - |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | - |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | - |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | - |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | - |
| 10 | Biogen | 30.87 Bn | 26.59 Bn | 1.82 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2015 | -19.00 Mn |
| Dec 31, 2014 | -14.90 Mn |
| Dec 31, 2013 | -9.30 Mn |
| Dec 31, 2012 | -8.70 Mn |
| Dec 31, 2011 | 6.10 Mn |
| Sep 30, 2009 | -400,000.00 |